Boehringer’s Trajenta Enters China As DPP-4 Latecomer, But Playing Field Still Level
This article was originally published in PharmAsia News
Executive Summary
Boehringer Ingelheim’s first diabetes product, Trajenta, has been approved in China. It enters China as the fourth DPP-4, but it may not have far to catch up given the reimbursement landscape.